Alteration in the expression of cdk4 and cdk6 proteins in oral cancer and premalignant lesions

Poomsawat, Sopee; Buajeeb, Waranun; Khovidhunkit, Siribang-on Piboonniyom; Punyasingh, Jirapa

doi:10.1111/j.1600-0714.2010.00909.x

Cited by 49 publications

(44 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CDK5 has been shown to be involved in lung cancer (Choi et al 2009;Liu et al 2010). The expression of CDK 6 is also altered in oral cancer (Poomsawat et al 2010). CDK7 polymorphisms have been shown to have an eVect on breast cancer (Jeon et al 2010).…”

Section: Introductionmentioning

confidence: 99%

“…CDK2 expression or activity has been used for the prognosis of breast (Kim et al 2008), ovarian (Marone et al 1998) and oral (Mihara et al 2001) cancers. Aberrant expression of CDK4 has been implicated in ovarian (Kusume et al 1999), urinary bladder , endometrial (Semczuk et al 2004) and oral (Poomsawat et al 2010) cancers. CDK5 has been shown to be involved in lung cancer (Choi et al 2009;Liu et al 2010).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The CDK inhibitors in cancer research and therapy

Cicenas

Valius²

2011

J Cancer Res Clin Oncol

222

176

View full text Add to dashboard Cite

Chemical compounds that interfere with an enzymatic function of kinases are useful for gaining insight into the complicated biochemical processes in mammalian cells. Cyclin-dependent kinases (CDK) play an essential role in the control of the cell cycle and/or proliferation. These kinases as well as their regulators are frequently deregulated in diVerent human tumors. Aberrations in CDK activity have also been observed in viral infections, Alzheimer's, Parkinson's diseases, ischemia and some proliferative disorders. This led to an intensive search for small-molecule CDK inhibitors not only for research purposes, but also for therapeutic applications. Here, we discuss seventeen CDK inhibitors and their use in cancer research or therapy. This review should help researchers to decide which inhibitor is best suited for the speciWc purpose of their research. For this purpose, the targets, commercial availability and IC 50 values are provided for each inhibitor. The review will also provide an overview of the clinical studies performed with some of these inhibitors.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The CDK inhibitors in cancer research and therapy

Cicenas

Valius²

2011

J Cancer Res Clin Oncol

222

176

View full text Add to dashboard Cite

show abstract

“…However, a number of studies have been reported on expression of CDKs in human malignancies indicating its oncogenic property. [121617]…”

Section: Discussionmentioning

confidence: 99%

“…in their study on endometrial carcinomas who concluded it as having a different “functional status” or a “resting status” of CDK4. [12]…”

Section: Discussionmentioning

confidence: 99%

“…have found that CDK4 expression in normal mucosa was considerably lower than OL with dysplasia and OSCC suggesting that CDK4 might be implicated in the early event of carcinogenesis. [12] Piboonniyom et al . have found the over-expression of CDK4 in OL with mild dysplasia and OSCC and the over-expression of CDK6 in only OSCC and suggested that CDK4 might be involved in the early event of carcinogenesis of OSCC and CDK6 might play a role later.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immunohistochemical characterization of cyclin dependent kinase-4 in different histological grades of oral leukoplakia and oral squamous cell carcinoma

Shyam

Rao

Narang

et al. 2014

J Oral Maxillofac Pathol

View full text Add to dashboard Cite

Background:Cyclin dependent kinase-4 (CDK4) encoded by CDK gene, is a heterodimer protein of cell cycle in G1-S transition. This study aimed to characterize the CDK4 immunoreactivity in different histological grades of oral leukoplakias (OLs) and oral squamous cell carcinomas (OSCCs) and also aims to discuss its probable role in the tumor biogenesis.Materials and Methods:Expression of CDK4 was investigated in total of 52 samples including OL (15), OSCCs (30) and normal oral tissues (07). A labeled Streptavidin-Biotin immunohistochemistry assay was performed and staining intensity was evaluated.Results:The staining pattern was similar in all tissues and was located in both nuclei and cytoplasm. Dysplastic epithelium displayed a progressive increase in nuclear expression of CDK4 when compared to normal tissues. Also, positive staining cytoplasm was highly evident in OSCC with loss of differentiation.Conclusion:Our study indicated a progressive over expression of CDK4 from normal to leukoplakias (various histological grades of dysplasias) and OSCCs.

show abstract

Anticancer effects of picrasidine I on oral squamous cell carcinoma

Yang

Hsieh

Chuang

et al. 2021

Environmental Toxicology

View full text Add to dashboard Cite

Picrasidine I is a dimeric alkaloid derived from a Southern Asian plant Picrasma quassioides and demonstrated to possess pharmacological activities, such as anti‐inflammatory and anti‐osteoclastogenic effects. However, its potential anticancer effect remains unclear. In the present study, anticancer activity of picrasidine I was assessed by treating oral squamous cell carcinoma cells with different concentrations of picrasidine I (20, 30, and 40 μM) for 24, 48, and 72 h. The findings revealed that picrasidine I reduced the cell viability in a dose‐dependent manner. Picrasidine I exerted its cytotoxic effect through arresting cell cycle at G2/M phase by downregulating cyclin A, cyclin B, CDK4, and CDK6, and inducing apoptosis in oral cancer cells. The induction of apoptosis was evidenced by increasing expression of death receptors, disruption of mitochondrial membrane potential, increased activation of PARP and caspases 3, 8, and 9, enhanced expression of proapoptotic mediators (Bak and Bim L/S), and reduced expression of antiapoptotic mediators (Bcl‐2 and Bcl‐xL). Moreover, analysis of MAPK signaling pathway revealed that picrasidine I‐mediated proapoptotic activities by downregulating JNK phosphorylation. Taken together, the study identifies picrasidine I as a potent anticancer agent that can be used as a therapeutic intervention against oral squamous cell carcinoma.

show abstract

Alteration in the expression of cdk4 and cdk6 proteins in oral cancer and premalignant lesions

Abstract: Overexpressions of cdk4 and cdk6 were observed in OSCC, indicating that these two proteins play a crucial role in OSCC. The aberrant expression of cdk4 was found in OL with dysplasia, suggesting that cdk4 may be involved in the early event of carcinogenesis.

Cited by 49 publications

References 35 publications

The CDK inhibitors in cancer research and therapy

The CDK inhibitors in cancer research and therapy

Immunohistochemical characterization of cyclin dependent kinase-4 in different histological grades of oral leukoplakia and oral squamous cell carcinoma

Anticancer effects of picrasidine I on oral squamous cell carcinoma

Contact Info

Product

Resources

About